CeriBell (NASDAQ:CBLL) Shares Gap Down – Time to Sell?

CeriBell, Inc. (NASDAQ:CBLL) gapped down prior to trading on Wednesday . The stock had previously closed at $19.90, but opened at $18.82. CeriBell shares last traded at $18.9310, with a volume of 119,076 shares changing hands.

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Beat on the quarter — CeriBell reported GAAP EPS of -$0.36 vs. consensus -$0.43 and revenue of $24.78M (above estimates), demonstrating continued top-line growth. Zacks: CeriBell Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: FY2026 revenue guidance set to $111M–$115M, roughly consistent with consensus (Street at ~$112.7M), which keeps expectations intact for continued revenue expansion. Business Insider: Financial Results
• Positive Sentiment: Strong liquidity and low leverage (very high quick/current ratios and low debt-to-equity) reduce near-term financing risk. MarketBeat: Q4 Release & Ratios
• Neutral Sentiment: Earnings call and full transcripts are available for detail on adoption, margin path and market expansion; read the call to assess management’s cadence on commercial traction. Seeking Alpha: Q4 2025 Call Transcript Yahoo: Q4 Highlights
• Negative Sentiment: Still loss-making with negative net margin (~-63%) and negative ROE — profitability remains a multi-quarter objective, limiting near-term EPS upside. MarketBeat: Earnings Summary
• Negative Sentiment: Insider selling — Director Josef Parvizi sold 16,714 shares (and has sold earlier tranches), which can create perception of founder/liquidity selling pressure. InsiderTrades: Parvizi Sale
• Negative Sentiment: Technical/analyst pressure: shares are below the 50-day moving average and some firms have trimmed targets (mixed analyst views may cap a post-earnings pop). MarketBeat: Analyst Notes & Technicals

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on CBLL shares. JPMorgan Chase & Co. decreased their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Canaccord Genuity Group increased their price objective on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. TD Cowen restated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. Finally, BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Trading Down 8.1%

The company has a fifty day moving average of $21.26 and a two-hundred day moving average of $16.17. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $678.15 million, a price-to-earnings ratio of -12.08 and a beta of 1.03.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The business had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. On average, research analysts expect that CeriBell, Inc. will post -2.46 EPS for the current year.

Insider Buying and Selling at CeriBell

In other news, Director Josef Parvizi sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $21.49, for a total value of $537,250.00. Following the completion of the sale, the director directly owned 772,652 shares of the company’s stock, valued at $16,604,291.48. This trade represents a 3.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William W. Burke sold 32,728 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $22.02, for a total value of $720,670.56. Following the transaction, the director directly owned 17,391 shares in the company, valued at $382,949.82. This represents a 65.30% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 336,370 shares of company stock worth $6,863,908. 20.10% of the stock is currently owned by company insiders.

Institutional Trading of CeriBell

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its position in CeriBell by 41.4% during the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after buying an additional 854 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares during the period. Ameritas Investment Partners Inc. increased its stake in CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares in the last quarter. Deutsche Bank AG increased its stake in CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in CeriBell by 10.8% during the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock worth $342,000 after purchasing an additional 1,514 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.